admin

Cancer Research: 5 Reasons You Should Apply

1. Free lab space: provisions, access to mouse study and technicians
2. Mentorship: Experienced scientific team with commercial expertise and successful serial biohealth entrepreneur and team
3. Prime location in the center of the MD Biohealth corridor
4. $10,000 a month in support: $5,000 cash/$5,000 “in-kind”
5. No strings attached: no equity participation or IP rights required

Immunomic Therapeutics is committed to providing a workplace that bolsters scientific ideas. The Cancer Discovery Incubator will enable and accelerate beginning ventures with the capacity for measurable change in oncology health. The goal is to empower the beneficiary to conduct proof-of-concept experiments and ultimately, attract funding, partnerships, and fuel growth.

Walking around San Francisco’s Union Square during biotech conference season in January—during this time of industry prosperity—you might expect it to be crawling with brainy young people. You might expect hot startups to come from students and postdocs, like in the tech industry, with VCs scrambling to get in on the ground floor.

The Trump administration will have an opportunity to reevaluate policies that affect innovation and technological development. How can federal policies promote broadband buildout, spur investment in intelligent infrastructure, encourage research and development, and advance a host of other actions that have the potential to improve productivity and the U.S. economy? Join ITIF and the Technology Policy Institute to discuss how the Trump administration can accelerate the pace of innovation in the U.S. economy.

With CoapTech, Steven Tropello and Howard Carolan are working on new technology for replacing patients’ feeding tubes.

The approach, called Percutaneous Ultrasound Gastrostomy, or PUG, utilizes a device with magnets that doctors can use to guide a feeding tube into place. It also features an ultrasound that allows doctors to see what is happening inside the body as the tube as it goes to the stomach, and identify the safest site for the tube to be placed.

It’s hard to get excited about a biotech shared-space in 2016.

Four years ago, it was an exciting and rapidly diversifying field. Now incubators are par for the course, with most Big Pharma and many institutions operating their own version.

Mass Innovation Labs was late to the game, opening in May 2015. But it is clearly doing something different.

Honoring those who see past the present to define the future

The future is not granted. It is born from the imagination of entrepreneurs. If you are a successful entrepreneur or have been inspired by an enterprising trailblazer, we’d like you to submit a nomination to the EY Entrepreneur Of The Year® 2017 program.

About the Entrepreneur Of The Year Program

Since 1986, EY has celebrated the accomplishments of thousands of entrepreneurs who have shaped the way we live, work and play. We recognize and honor these inspiring individuals through the Entrepreneur Of The Year.

Over three decades, the program has grown to span more than 145 cities, in more than 60 countries, and now boasts a roster of nearly 10,000 visionary trailblazers here in the US.

Despite a recent tapering of year-on-year growth, the global market for prescription drugs is forecast to reach $1.5 trillion per year by 2021, a 33 percent increase from 2016.

That’s according to a new report by the QuintilesIMS Institute, the research arm of the healthcare informatics company QuintilesIMS.

Ascension Ventures (AV) has finalized its latest strategic venture capital fund at $255 million. This fourth fund for AV, CHV IV, L.P., brings the firm’s total assets under management to more than $800 million. The new fund is backed by 13 health system partners, which enable AV to continue to add value to its portfolio companies while simultaneously delivering financial and strategic returns to the partners.

A defining moment in modern biology occurred on July 24, 1978, when biotechnology pioneer Robert Swanson, who had recently co-founded Genentech, brought two young scientists to dinner with Thomas Perkins, the legendary venture capitalist. As they stood outside Perkins’s magnificent mansion in Marin County, with its swimming pool and garden and a view of the Golden Gate Bridge, Swanson turned to his two young colleagues and said, “This is what we’re all working for.”

Inova announced today that Milton L. Brown, MD, PhD, has joined Inova where he will serve as director of the new Inova Center for Drug Discovery and Development and as deputy director for Drug Discovery for the Inova Schar Cancer Institute (ISCI). Dr. Brown is a physician scientist who has expertise in the design, synthesis, and evaluation of new drugs and is one of only a handful of physician scientists in the United States who hold a PhD in synthetic chemistry and an MD. He comes to Inova from Georgetown University Medical Center where he was founding director of the Drug Discovery Program (DDP).